Medicare Drug Prices Drop 30% Under Inflation Reduction Act 2026

Prescription drug costs are a major challenge for Medicare beneficiaries. The Inflation Reduction Act's drug price negotiation program aims to reduce how much seniors pay for essential medications. Its inflation rebate provisions have already led to savings on over 120 drugs. Many Medicare recipients now pay substantially less for necessary treatments than they did a few years ago.

The Medicare drug price negotiation process will reduce costs for approximately 5.3 million Medicare beneficiaries who used these medications between November 2023 and October 2024. About 11 million people with Medicare Part D will benefit from the $2,000 annual out-of-pocket cap beginning in 2025, saving a combined $7.2 billion (about $600 per enrollee). The Congressional Budget Office estimates that the drug negotiation provisions will save Medicare $98.5 billion over 10 years from 2022 to 2031. The Centers for Medicare and Medicaid Services (CMS) will allocate about $2.9 billion of the $3 billion in appropriated funds to carry out these negotiations through fiscal year 2033.

This guide examines how the Inflation Reduction Act affects Medicare drug pricing, which medications see price reductions, and who benefits most from these changes. Total U.S. drug spending reached $722.5 billion in 2023. These reforms offer relief for Medicare recipients who need affordable access to their medications.

• CMS announces 30% Medicare drug price drop for 2026
• How Medicare drug price negotiation was implemented
• Which drugs are affected and who benefits most
• Bottom line
• Key takeaways
• FAQs

CMS announces 30% Medicare drug price drop for 2026

The Centers for Medicare & Medicaid Services (CMS) announced price reductions for the first 10 drugs selected under the Medicare Drug Price Negotiation Program in August 2024. These negotiated prices, officially called Maximum Fair Prices, take effect January 1, 2026.

The negotiated prices represent discounts of 38% to 79% off list prices. Here are some examples:

• Januvia (diabetes medication): Price drops from $527 to $113 per 30-day supply – a 79% reduction
• Enbrel (rheumatoid arthritis treatment): Decreases from $7,106 to $2,355 – a 67% discount

Had these negotiated prices been in effect during 2023, they would have saved an estimated $6 billion in covered prescription drug costs—22% lower spending across the selected drugs. When implemented in 2026, Medicare beneficiaries will save an estimated $1.5 billion in out-of-pocket costs.

CMS negotiated with drug manufacturers throughout the process. CMS revised offers upward and manufacturers adjusted counteroffers downward. Five drugs reached agreement during negotiation meetings; the remaining five manufacturers accepted CMS's final written offers before the deadline.

How Medicare drug price negotiation was implemented

The Inflation Reduction Act of 2022 allows the Centers for Medicare & Medicaid Services (CMS) to directly negotiate prices for certain high-cost prescription drugs. The first negotiation cycle started in 2023, following the law's August 2022 signing.

CMS selected the highest-expenditure Medicare Part D drugs without generic competition that had been approved at least seven years prior for small-molecule drugs or eleven years for biologics. The negotiation process followed these phases:

1. September 1, 2023: CMS published the list of 10 Medicare Part D drugs selected for the first negotiation cycle
2. October 1, 2023: Manufacturers signed agreements to participate in negotiations
3. February 1, 2024: CMS sent initial price offers with justifications to manufacturers
4. March 2, 2024: Manufacturers responded with counteroffers
5. Spring/Summer 2024: Three negotiation meetings were held with each manufacturer
6. August 1, 2024: Negotiation period concluded with agreements on all 10 drugs
7. January 1, 2026: Negotiated prices become effective

During negotiations, CMS considered research and development costs, production costs, federal financial support, patent information, therapeutic advances, and comparative effectiveness.

The second negotiation cycle targets 15 additional Part D drugs for 2027 implementation, with negotiations occurring throughout 2025. For 2028, 15 more drugs from both Part D and Part B will be selected. After that, 20 additional drugs will be chosen each year.

Which drugs are affected and who benefits most

The first round targets medications that millions of Americans depend on for chronic conditions. These ten drugs treat diabetes, heart disease, blood clots, and cancer, with price reductions ranging from 38% to 79% off list prices.

Medicare will expand negotiations to include 15 additional medications for 2027, including Ozempic and Wegovy for diabetes and weight management. These drugs represented approximately 20% of total Medicare Part D spending in 2023.

Who saves the most varies by individual circumstances:

• Approximately 8.8 million Medicare beneficiaries who used these medications in 2023 will see direct savings
• About 11 million enrollees hitting the new $2,000 out-of-pocket cap in 2025 will save a combined $7.2 billion, averaging $600 per person
• Those without additional financial assistance will save even more, averaging $1,100 annually

States like California, Florida, and Texas each have over 100,000 beneficiaries who will benefit. Patients requiring expensive treatments for cancer, rheumatoid arthritis, and other serious conditions may save thousands annually. A patient using Stelara could see their 30-day supply coinsurance drop from $3,400 to $1,100.

Bottom line

Medicare drug price negotiations, established by the Inflation Reduction Act, will lower costs for millions of seniors who rely on essential medications. Price reductions of 38% to 79% for the first ten drugs take effect in 2026, with the program expanding to cover additional high-cost drugs through 2031.

Seniors who have struggled to afford both medications and other necessities will see significant relief. Starting in 2025, a $2,000 annual out-of-pocket cap will protect Medicare beneficiaries from high medication costs.

The program is projected to save Medicare $98.5 billion over ten years. This reflects both reduced costs to individual beneficiaries and savings to the overall Medicare program. The negotiation process considers pharmaceutical development costs alongside fair pricing for patients.

Medicare recipients can expect these benefits to keep expanding through 2031 as more medications enter the negotiation process. The first round shows these negotiations can deliver real savings while maintaining access to necessary treatments.

Key takeaways

The Inflation Reduction Act's Medicare drug price negotiation program provides significant savings for millions of seniors, making essential medications more affordable.

• First 10 negotiated Medicare drugs see 38–79% price reductions starting January 2026, saving patients billions annually

• Over 8.8 million Medicare beneficiaries will benefit directly, and 11 million more will save over $600 due to the new $2,000 out-of-pocket cap

• The program will expand from 10 drugs in 2026 to more than 20 annually by 2031, focusing on high-cost medications for diabetes, cancer, and heart disease

• The Congressional Budget Office projects $98.5 billion in Medicare savings over 10 years, improving prescription drug affordability

This reform helps seniors who previously had to choose between essential medications and their daily needs. The negotiation process shows that the government can achieve real healthcare cost reductions.

FAQs

Q1. Which medications are included in Medicare's drug price negotiations? Medicare has selected 10 high-expenditure drugs for the first round, including treatments for diabetes, heart disease, blood clots, and cancer. The program expands annually, with 15 additional drugs targeted for 2027 and more in subsequent years.

Q2. How much will Medicare beneficiaries save? For the first 10 negotiated drugs, price reductions range from 38% to 79% off list prices. About 11 million people with Medicare Part D will have a new $2,000 annual out-of-pocket cap starting in 2025, saving an average of $600 per enrollee.

Q3. When will the negotiated drug prices take effect? The negotiated prices for the first 10 drugs take effect on January 1, 2026. The program expands in later years, adding more drugs to the negotiation list.

Q4. Are there any drugs excluded from the Medicare price negotiations? Yes. Orphan drugs approved to treat a single rare disease or condition are excluded, as specified in the Inflation Reduction Act of 2022.

Q5. How will Medicare drug price negotiations impact overall healthcare costs? The Congressional Budget Office estimates the drug negotiation provisions will save Medicare $98.5 billion over 10 years from 2022 to 2031. This should help reduce overall healthcare costs and improve medication access for Medicare recipients.